Nadine Henderson
Nadine is health economist whose research focuses on the methodological and policy challenges related to health technology assessment (HTA). She has experience researching these issues for specialised technologies and contexts including rare diseases, gene therapies and other innovative therapies. Complementary to this topic, Nadine has expertise in measuring and valuing health outcomes through the development of EQ–5D ‘bolt–on’ items and assessing the appropriateness of the EORTC QLU–C10D. Experienced in a range of methodologies, her specialty lies in qualitative research.
She is also interested in the timely policy issue of the environmental sustainability of the pharmaceutical industry and health systems. Her projects in this area include supporting the era of green pharmaceuticals in the UK and estimating the health and cost impacts of a greater uptake of vegan diets.
She is a member of the UK’s Health Economists’ Study Group (HESG) Early Career Researcher (ECR) sub-committee and sits on Independent Advisory Board of CMAC, a medicines manufacturing research centre led from the University of Strathclyde. She has a MSc in Health Economics from the University of York and a BSc (Hons) in Economics from Lancaster University.
Publications and Insights
- Publication: An Analysis of NICE’s Optimised Decisions from 2015 to 2024
- Publication: Challenges and Solutions for Budget Impact Analysis of Gene Therapies
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Insight: EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
- Insight: Infectious disease: another reason to try Veganuary for the NHS
- Publication: Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
- Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
- Insight: Could Plant-based Diets Transform Health Care Spending?
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Publication: The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
- Insight: How Restrictive are NICE ‘Optimised’ Decisions?
- Insight: ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
- Insight: ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
- Insight: Rare Disease Day 2022
- Publication: Supporting the Era of Green Pharmaceuticals in the UK
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
- Publication: A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
- Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
- Insight: A NICE Wind of Change? The What and So What of the NICE Methods Consultation
- New: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
- Publication: Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
- Publication: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions